Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Harding Loevner urges caution regarding the extreme concentration and demanding valuations in US AI platforms, advocating for a globally diversified approach focused on high-quality structural enablers.
Full Quick Take
Harding Loevner urges caution regarding the extreme concentration and demanding valuations in US AI platforms, advocating for a globally diversified approach focused on high-quality structural enablers.
Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncratic value in an otherwise expensive and concentrated global market.
Full Quick Take
Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncratic value in an otherwise expensive and concentrated global market.
The rapid Q2 recovery from the Q1 drawdown was driven by emotion rather than fundamental data, returning the market to highly concentrated and risky valuation levels. Bahl & Gaynor advises shifting toward diversified, valuation-disciplined dividend growth strategies to protect gains and manage downside risk.
Full Quick Take
The rapid Q2 recovery from the Q1 drawdown was driven by emotion rather than fundamental data, returning the market to highly concentrated and risky valuation levels. Bahl & Gaynor advises shifting toward diversified, valuation-disciplined dividend growth strategies to protect gains and manage downside risk.
